ProclaRx Hosts Networking Event to Raise Awareness of Its Groundbreaking Anti-Infective Technology

Monday, July 18, 2016 Men´s Health News
Email Print This Page Comment bookmark
Font : A-A+

Ohio Biotech Company Committed to Improving Treatment of Patients Suffering from Advanced Bacterial Infections

COLUMBUS, Ohio, July 18, 2016 /PRNewswire/ -- On Tuesday, July 12, 2016, ProclaRx, a biotechnology

company developing innovative therapeutics for patients suffering from serious bacterial infections, held an awareness and networking event for interested individuals from the Ohio community. The event was intended to educate business and community leaders on the positive impact the ProclaRx technology could potentially have on those suffering from chronic ear infections as well as the resources required to get the technology to market.

Logo -

The evening event was held at the home of Karl O. Elderkin, the Managing Partner at Athenian Venture Partners. The festivities were kicked off by Ohio University President, Dr. Roderick J. McDavis, with a formal presentation on the importance of entrepreneurship, commercialization of science, and the important role the community plays in advancing technology. ProclaRx CEO, Dr. Joseph D. Kittle, Jr., presented the company to the audience. Other featured presenters and notable attendees included Chris Gerig, Attorney at Gerig and Gerig; Debbie Phillips Bower, Owner of RE/MAX Premier Choice; George K. Richards, President of Capital Drugs; Tim O'Dell, CEO of CF Bank; Bob Milbourne, President of RHM Advisors; John Kopchick, PhD, Distinguished Professor of Molecular Biology at Ohio University; Jack Ellis, Emeritus Chief Executive Officer and Executive Director of The Ohio University Foundation, Ohio University; and Jim Sergi, President of CSSi LifeSciences™.

"The outpouring of support from Ohio University, the Athens Innovation Center and community, and Athenian Ventures at Tuesday's event was greatly appreciated," said Nick Henderson, Chairman, ProclaRx. "ProclaRx is hopeful to one day bring this game-changing technology to market, which could potentially benefit hundreds of thousands of people and children suffering from chronic bacterial infections."

ProclaRx's technology is envisioned to address unmet needs in patients suffering from not only ear infections, but also chronic sinusitis. The treatment is intended to disrupt and clear bacterial biofilm infections.

CSSi LifeSciences™ has been partnering with ProclaRx over the past year. "We are very excited to collaborate with the ProclaRx team and recognize the importance these treatments of recurrent infections may one day offer to patients," said Jim Sergi, President, CSSi LifeSciences™. "We strongly believe that ProclaRx is going to continue making great strides in the industry and beyond." During the event, Jim discussed the clinical and regulatory pathway for commercialization of the ProclaRx technology.

Established in 2014, ProclaRx and its staff of experienced scientists are committed to eliminating the causes of countless chronic and recurrent human infections. The Columbus-based company prides itself on developing and commercializing anti-infective technologies, with the goal of eliminating biofilms and helping cure diseases.With $6.5 million invested to-date, ProclaRx is seeking additional strategic partners to help further its continued efforts to develop multiple innovative therapeutics for patients suffering from serious bacterial infections.

To learn more about ProclaRx, please visit If you are interested in supporting ProclaRx's efforts, please contact Nick Henderson for more information at

About ProclaRx:ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, chronic suppurative otitis media, and CVID sinusitis. Visit, call 949-302-2165, or email

Media Contacts:Courtney GaddiPublic Relations & Marketing CoordinatorCSSi(443) 308-5831Email

To view the original version on PR Newswire, visit:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store